An Open-Label Study to Assess the Drug-Drug Interaction Potential of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects.

Trial Profile

An Open-Label Study to Assess the Drug-Drug Interaction Potential of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs Oritavancin (Primary) ; Warfarin
  • Indications Bacteraemia; Gram-positive infections; Skin and soft tissue infections
  • Focus Pharmacokinetics
  • Sponsors The Medicines Company
  • Most Recent Events

    • 30 Oct 2016 Results presented at the IDWeek 2016
    • 02 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.record.
    • 16 Jul 2015 Planned End Date changed from 1 May 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top